• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

AJMC® in the Press, July 30, 2021


Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

An article by BenefitsPRO referenced a study published in the July 2021 issue of The American Journal of Managed Care® (AJMC®), titled “Reduced Medical Spending Associated With Integrated Pharmacy Benefits.” In the study, authors found that Blue Cross and Blue Shield of Louisiana members covered by an integrated pharmacy benefit, as opposed to a pharmacy carve-out, experienced slower growth in medical spending.

A piece by Fierce Pharma cited an article by AJMC®’s sister site The Center for Biosimilars®, titled “FDA Approves Semglee Insulin Glargine as First Interchangeable Biosimilar.” The article covered the FDA’s approval of Biocon Biologics’ Semglee insulin glargine as an interchangeable biosimilar, referencing Lantus.

An article by the Center for American Progress referenced a June 2019 contributor post published on AJMC.com, the website of AJMC®. The contributor article, titled “The Deadly Costs of Insulin,” details the significant price increases of insulin treatment, from $14 for 1 vial in 2001 to $275 in 2019.

Another piece by Fierce Pharma included an article from The Center for Biosimilars®. The article, “Pfizer Resolves Antitrust Lawsuit With J&J Over Remicade,” covered a Pfizer settlement with Johnson & Johnson (J&J) over a long-running dispute in which J&J was alleged to have blocked payers from covering Inflectra.

Related Videos
Leslie Fish, PharmD.
Mila Felder, MD, FACEP
Shawn Gremminger
Dr Lucy Langer
Dr Lucy Langer
Edward Arrowsmith, MD, MPH
Dr David Fajgenbaum | Image credit: The Castleman Disease Collaborative Network
Takiyah Durham, MBA, and Margaret Larkins-Pettigrew, MD
Takiyah Durham, MBA, Margaret Larkins-Pettigrew, MD
Related Content
© 2024 MJH Life Sciences
All rights reserved.